Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00178607
: September 15, 2005
Last Update Posted
: May 12, 2016
The University of Texas Health Science Center, Houston
Information provided by (Responsible Party):
Miguel Escobar, The University of Texas Health Science Center, Houston
To correlate the Human Leukocyte Antigen type and genetic defect with hemophilia A.
Condition or disease
One of the most serious complications of treatment in patients with hemophilia A or hemophilia B is the development of an inhibitor, which is an antibody that neutralizes the factor VIII or IX coagulant activity. Up to one fourth of patients with severe hemophilia A develop an inhibitor but at present it is not possible to predict which patients will develop such antibody. The ability to predict an inhibitor development at an individual level would greatly improve therapeutic approach to this serious problem
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
up to 99 Years (Child, Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Subjects with Severe Hemophilia A and a positive inhibitor
Severe Hemophilia A with an inhibitor level of 0.6 B.U. or higher